Biogen and Ionis presented Phase 2 CELIA results
Author: Michael
BioAge Labs has dosed the first participant in QU
Halia Therapeutics announced two posters at the A
Tenpoint Therapeutics has submitted a Marketing A
ImmunoBrain announced that Phase 1b data for IBC-
ProMIS presented data at the Alzheimer’s Associ
New analyses suggest Alzheon’s therapy may pro
The startup is betting that the future of longev
Eisai and Biogen presented data at the Alzheimer’s Association International Conference 2026 in London showing that a lecanemab subcutaneous autoinjector (LEQEMBI) produced exposure, efficacy and safety comparable to the approved intravenous initiation regimen in people with early Alzheimer’s disease. According to the company, once-weekly 500 mg subcutaneous administration demonstrated bioequivalence to the IV initiation regimen (10 mg/kg every two weeks) with an exposure ratio of 104% (90% confidence interval 99.1%–109%) and consistent exposure across body weight quartiles. The companies claim that amyloid reduction measured by PET, clinical efficacy on CDR-SB and incidence of ARIA-E were driven by lecanemab exposure rather…
Cognito Therapeutics presented exploratory cerebr